Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 445

1.

Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).

Kindler T, Breitenbuecher F, Kasper S, Estey E, Giles F, Feldman E, Ehninger G, Schiller G, Klimek V, Nimer SD, Gratwohl A, Choudhary CR, Mueller-Tidow C, Serve H, Gschaidmeier H, Cohen PS, Huber C, Fischer T.

Blood. 2005 Jan 1;105(1):335-40. Epub 2004 Sep 2.

2.

Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.

Jiang J, Paez JG, Lee JC, Bo R, Stone RM, DeAngelo DJ, Galinsky I, Wolpin BM, Jonasova A, Herman P, Fox EA, Boggon TJ, Eck MJ, Weisberg E, Griffin JD, Gilliland DG, Meyerson M, Sellers WR.

Blood. 2004 Sep 15;104(6):1855-8. Epub 2004 Jun 3.

3.

FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model.

Grundler R, Miething C, Thiede C, Peschel C, Duyster J.

Blood. 2005 Jun 15;105(12):4792-9. Epub 2005 Feb 17.

4.

Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).

Murata K, Kumagai H, Kawashima T, Tamitsu K, Irie M, Nakajima H, Suzu S, Shibuya M, Kamihira S, Nosaka T, Asano S, Kitamura T.

J Biol Chem. 2003 Aug 29;278(35):32892-8. Epub 2003 Jun 18.

5.

AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.

Choudhary C, Schwäble J, Brandts C, Tickenbrock L, Sargin B, Kindler T, Fischer T, Berdel WE, Müller-Tidow C, Serve H.

Blood. 2005 Jul 1;106(1):265-73. Epub 2005 Mar 15.

6.

Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.

Grundler R, Thiede C, Miething C, Steudel C, Peschel C, Duyster J.

Blood. 2003 Jul 15;102(2):646-51. Epub 2003 Mar 27.

7.

Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.

Tse KF, Allebach J, Levis M, Smith BD, Bohmer FD, Small D.

Leukemia. 2002 Oct;16(10):2027-36.

8.

FLT3 mutations in acute myeloid leukemia cell lines.

Quentmeier H, Reinhardt J, Zaborski M, Drexler HG.

Leukemia. 2003 Jan;17(1):120-4.

PMID:
12529668
9.

Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.

Spiekermann K, Bagrintseva K, Schwab R, Schmieja K, Hiddemann W.

Clin Cancer Res. 2003 Jun;9(6):2140-50.

10.

Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.

Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Müller C, Grüning W, Kratz-Albers K, Serve S, Steur C, Büchner T, Kienast J, Kanakura Y, Berdel WE, Serve H.

Blood. 2000 Dec 1;96(12):3907-14.

11.

The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.

Spiekermann K, Dirschinger RJ, Schwab R, Bagrintseva K, Faber F, Buske C, Schnittger S, Kelly LM, Gilliland DG, Hiddemann W.

Blood. 2003 Feb 15;101(4):1494-504. Epub 2002 Oct 24.

12.

Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts.

Birkenkamp KU, Geugien M, Lemmink HH, Kruijer W, Vellenga E.

Leukemia. 2001 Dec;15(12):1923-31.

PMID:
11753614
13.

Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines.

Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H, Naoe T.

Oncogene. 2000 Feb 3;19(5):624-31.

14.

FLT3/ITD mutation signaling includes suppression of SHP-1.

Chen P, Levis M, Brown P, Kim KT, Allebach J, Small D.

J Biol Chem. 2005 Feb 18;280(7):5361-9. Epub 2004 Dec 1.

15.

FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.

Taketani T, Taki T, Sugita K, Furuichi Y, Ishii E, Hanada R, Tsuchida M, Sugita K, Ida K, Hayashi Y.

Blood. 2004 Feb 1;103(3):1085-8. Epub 2003 Sep 22.

16.

[Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].

Müller-Tidow C, Steur C, Mizuki M, Schwäble J, Brandts C, Berdel WE, Serve H.

Dtsch Med Wochenschr. 2002 Oct 18;127(42):2195-200. German.

PMID:
12397548
17.

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, Grandin W, Lebwohl D, Wang Y, Cohen P, Fox EA, Neuberg D, Clark J, Gilliland DG, Griffin JD.

Blood. 2005 Jan 1;105(1):54-60. Epub 2004 Sep 2.

18.

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.

Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R, Naoe T.

Blood. 2001 Apr 15;97(8):2434-9.

19.

AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.

Barbarroja N, Torres LA, Rodriguez-Ariza A, Valverde-Estepa A, Lopez-Sanchez LM, Ruiz-Limon P, Perez-Sanchez C, Carretero RM, Velasco F, López-Pedrera C.

Exp Hematol. 2010 Aug;38(8):641-52. doi: 10.1016/j.exphem.2010.03.017. Epub 2010 Apr 7.

PMID:
20380868
20.

Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.

Bagrintseva K, Schwab R, Kohl TM, Schnittger S, Eichenlaub S, Ellwart JW, Hiddemann W, Spiekermann K.

Blood. 2004 Mar 15;103(6):2266-75. Epub 2003 Nov 6.

Items per page

Supplemental Content

Write to the Help Desk